("Biodexa" or the "Company") About Biodexa Pharmaceuticals PLC MTX110 is a solubilised formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity. Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be ...

June 10, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain on June 22, 2024. Carol Burke, MD, ...

For more information, please contact: Biodexa Pharmaceuticals PLC Stephen Stamp, CEO, CFO June 10, 2024 Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that 12 month data of a Phase 2 clinical trial of eRapa in Familial Adenomatous Polyposis ("FAP") are to be presented at the prestigious biennial InSIGHT 2024 meeting in Barcelona, Spain o ...

AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 6, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biodexa Pharmaceuticals PLC (Exact name of registrant as specified in its charter) England and Wales 2834 Not Applicable (State or Other Jurisdiction of Incorporation or Organization) (Primary Standard Industrial Classification Code Number) (IRS Employer Identification No.) 1 Caspian ...

May 22, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercis ...

May 22, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Biodexa Announces $7 Million of Gross Proceeds from Warrant Exercises Proceeds Cover Year 1 eRapa Phase 3 Obligations, Unlocking Twice that Amount in Non-dilutive Grant Funding Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces $7 million of gross proceeds from the exercis ...

May 21, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual Meeting Overall 83% non-progression rate at 6 Months Statistically Significant decrease in overall mean polyp burden at 6 months (p=0.04) Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmace ...

Core Insights - Biodexa Pharmaceuticals PLC announced positive Phase 2 clinical trial results for eRapa™ in treating Familial Adenomatous Polyposis (FAP), with an overall 83% non-progression rate at six months and a statistically significant 24% reduction in polyp burden (p=0.04) [2][6][7] Company Overview - Biodexa Pharmaceuticals PLC is a clinical stage biopharmaceutical company focused on developing innovative products for diseases with unmet medical needs, including eRapa for FAP and other treatments for type 1 diabetes and rare brain cancers [12][13] Clinical Trial Details - The Phase 2 study was an open-label trial conducted across seven U.S. centers, involving 30 adult patients with a median age of 43 years, assessing safety, tolerability, and polyp burden changes over a 12-month treatment period [4][5] - Patients were divided into three dosing cohorts, with the primary endpoints being safety and percentage change in polyp burden at six months [5] Results Summary - At six months, 78% of patients in the duodenum and 86% in the colorectum were classified as non-progressors, with a significant number showing partial response [6][7] - Only two drug-related Grade 3 Serious Adverse Events were reported, and 97% of patients remained on treatment at the six-month mark [6][7] About eRapa - eRapa is a proprietary oral formulation of rapamycin, an mTOR inhibitor, designed to improve bioavailability and reduce toxicity compared to existing rapamycin formulations [8][14] - The drug has received Orphan Designation in the U.S. and plans to seek similar designation in Europe, targeting a significant unmet need in FAP treatment [9] Funding and Support - The study received partial funding of $20 million from the Cancer Prevention and Research Institute of Texas, which has invested significantly in cancer research and prevention initiatives [3][10]

April 30, 2024 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa’s Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that’s its licensor E ...

April 30, 2024 Biodexa Pharmaceuticals PLC("Biodexa" or the "Company") Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting Biodexa Pharmaceuticals PLC, (NASDAQ:BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce that's its licensor Em ...